Exhibit 99.1 Legend Biotech Reports Full-Year 2022 Results and Recent Highlights CARTITUDE-4, a Phase 3 study of CARVYKTI® (ciltacabtagene autoleucel) meets primary endpoint at the study’s first pre-specified interim analysis FDA clearance of IND application for LB2102 in Extensive Stage Small Cell Lung Cancer (SCLC) CARVYKTI® (ciltacabtagene autoleucel) receives approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with relapsed or refractory multiple myeloma Chi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR o SHELL COMPANY REPORT PURSUANT TO SECT ...

Inspired by the human element to advance cell therapy December 2021 Unleashing the power of patients Disclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authorit ...

Inspired by the human element to advance cell therapy October 2021 Unleashing the power of patients Disclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authority ...

Inspired by the human element to advance cell therapy September 2021 Unleashing the power of patients Disclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authori ...

Inspired by the human element to advance cell therapy May 2021 Unleashing the power of patients Disclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the agents will receive health authority app ...

Legend Biotech Corporation (NASDAQ:LEGN) Q4 2020 Earnings Conference Call March 18, 2021 8:00 AM ET Company Participants Jessie Yeung - Head of Corporate Finance & Investor Relations Ying Huang - Chief Executive Officer & Chief Financial Officer Conference Call Participants Matthew Harrison - Morgan Stanley Biren Amin - Jefferies Operator Ladies and gentlemen, thank you for standing by and welcome to the Legend Biotech Reports Fourth Quarter 2020 Financial Results. At this time, all participant lines are in ...

Inspired by the human element to advance cell therapy Fourth Quarter 2020 Results March 18, 2021 Unleashing the power of patients Disclaimer 2 This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for informational purposes and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established. There is no guarantee that the age ...